AROC vs CRC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AROC's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. Despite strong profitability metrics and robust earnings growth, elevated debt levels and weak technical momentum weigh on overall health. The stock trades above the Graham Number of $16.59 but below the growth-based intrinsic value of $44.55, suggesting a fair valuation given growth expectations. Analysts are bullish with a $31.56 target, though insider selling and a low technical trend score introduce caution.
CRC exhibits a stark divergence between analyst optimism and deteriorating fundamental data. While the Piotroski F-Score of 4/9 indicates a stable financial baseline, the company is facing a severe growth crisis with earnings plummeting 61.5% YoY. The current price of $64.74 trades slightly above the Graham Number ($62.17) and significantly above the growth-based Intrinsic Value ($29.05), suggesting the market is pricing in a recovery that is not yet visible in the data. Heavy insider selling and a bearish technical trend further offset the 'Strong Buy' analyst consensus.
Compare Another Pair
Related Comparisons
AROC vs CRC: Head-to-Head Comparison
This page compares Archrock, Inc. (AROC) and California Resources Corporation (CRC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.